Interleukin 5 News and Research

RSS

Specialized proteins could soak up excess cytokines in COVID-19 patients

One of the defining features of Covid-19 is the excessive immune response that can occur in severe cases. This burst of immune overreaction, also called a cytokine storm, damages the lungs and can be fatal.

16 Apr 2020

Cancer-causing mutation also promotes inflammation

Analyses of cell signals provide insight into the origin of severe inflammatory symptoms that appear in various types of blood cancer and point to possible therapeutic approaches: In around one-fourth of patients suffering from juvenile myelomonocytic leukemia, there is evidence of mutations in the so-called KRAS gene in the leukemia cells.

8 Apr 2020

Purdue scientists aim to use protein power to halt tumor growth

In 2018, approximately 324,000 men died from cancer in the United States. The combination of lung cancer, prostate cancer and colorectal cancer equated to half of those deaths.

7 Apr 2020

Immunosuppressant shows promise in addressing COVID-19 symptoms for patients with blood cancers

A case study of a patient in Wuhan, China, suggests that the immunosuppressant tocilizumab may be an effective COVID-19 treatment for very ill patients who also have multiple myeloma and other blood cancers.

5 Apr 2020

Researchers say that NSAIDs, JAK inhibitors and TNF blockers are safe to use in COVID-19

Amid the coronavirus disease (COVID-19) pandemic, many theories have emerged about the disease and the treatments that can in supportive care. A recent theory emerged that suggests non-steroidal anti-inflammatory drugs (NSAIDs) might exacerbate the symptoms of the novel coronavirus. Now, a new study shows that there is no evidence for or against the use of NSAIDS, particularly ibuprofen, for patients with COVID-19.

1 Apr 2020

New study helps identify drugs that are safe for treating COVID-19

A recent study has found that there is no evidence for or against the use of non-steroidal anti-inflammatory drugs such as ibuprofen for patients with COVID-19.

31 Mar 2020

COVID-19 and its effects on the cardiovascular system

Researcher have reviewed the evidence showing the effects of the SARS-CoV-2 or novel coronavirus infection (COVID-19) on the cardiovascular system. Their study titled, “Potential Effects of Coronaviruses on the Cardiovascular System: A Review,” was published in the latest issue of JAMA Cardiology.

29 Mar 2020

UC Davis launches two clinical trials to evaluate treatments for COVID-19

UC Davis Health has two clinical trials underway for hospitalized patients with severe COVID-19, the disease caused by the novel coronavirus, SARS-CoV-2.

27 Mar 2020

Combination produces more proliferative, enduring central memory T cells for cellular therapy

Treating T cells harvested from a patient with a combination of an epigenetic drug and a cytokine while expanding the cells in the lab re-programs them into a stronger T cell type that persists longer than its comrades, researchers at The University of Texas MD Anderson Cancer Center report in Cancer Immunology Research, a journal of the American Association for Cancer Research.

25 Mar 2020

New understanding of signaling molecule interleukin-2 can guide drug discovery efforts

The signaling molecule interleukin-2 (IL-2) has long been known to have powerful effects on the immune system, but efforts to harness it for therapeutic purposes have been hampered by serious side effects.

17 Mar 2020

Researchers discover a new mechanism of long-lasting pain relief

A group of researchers from Charité - Universitätsmedizin Berlin has discovered a new mechanism of long-lasting pain relief.

16 Mar 2020

Visceral fat gives signal to the brain that damages cognition

Excessive weight around our middle gives our brain's resident immune cells heavy exposure to a signal that turns them against us, setting in motion a crescendo of inflammation that damages cognition, scientists say.

3 Mar 2020

Boosting immune cells to treat eczema

A new drug regimen is reported to have marked benefits in treating the troublesome and distressing skin condition called eczema. The study, published in February 2020 in the journal Science Translational Medicine, shows that boosting the levels of a type of immune cell called natural killer cells can be a more effective way to treat eczema in a mouse study.

27 Feb 2020

Reduced stress associated with changes in plasma metabolite profile

Reduced stress is linked to changes in the profile of plasma metabolites, a new study from the University of Eastern Finland shows.

25 Feb 2020

Using newly discovered immune cell type to fight pancreatic cancer

Immunotherapy is showing great promise for treating cancer. But so far, this approach has been effective in only about 20% of all cancers. To advance those results, researchers are looking for new ways to mobilize the immune system to destroy tumors.

23 Feb 2020

Researchers identify a protein that aids in colorectal cancer metastasis

A protein that helps colorectal cancer cells spread to other parts of the body could be an effective treatment target.

20 Feb 2020

Study identifies precise receptor chain involved in atopic dermatitis

Atopic dermatitis, a chronic inflammatory disorder, affects some 30 million Americans every year. It is the most common cause of eczema, a condition marked by unbearably itchy, flaky patches of skin.

19 Feb 2020

Mediterranean diet promotes healthy aging with healthier gut microbiome

A new study published online in the journal Gut in February 2020 reports the striking health-promoting effects of switching to a Mediterranean diet for just one year. The results were due to an increase in the health and number of gut bacteria that favor a healthy diet.

17 Feb 2020

Novel formulation allows use of toxin from rattlesnake venom to control neuropathic pain

Crotoxin, extracted from the venom of the South American rattlesnake Crotalus durissus terrificus, has been studied for almost a century for its analgesic, anti-inflammatory and antitumor activities and as an even more powerful muscle paralyzer than botulinum toxin.

16 Feb 2020

Georgia State researcher receives $1.67 million federal grant to study gut immunity

Dr. Tim Denning, professor and associate director of the Institute for Biomedical Sciences at Georgia State University, has received a four-year, $1.67 million federal grant to study how an immunological pathway influences inflammatory signaling in the intestine that can lead to chronic human diseases such as inflammatory bowel disease.

9 Feb 2020